Literature DB >> 14642452

Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats--an MRI study.

Jeong Hyun Lee1, Yong-Kyu Lee, Makoto Ishikawa, Keiko Koga, Mari Fukunaga, Goro Miyakoda, Toyoki Mori, Tetsumi Hosokawa, Ki Whan Hong.   

Abstract

To investigate the effects of cilostazol on the hemispheric ischemic lesion, we monitored the apparent diffusion coefficient (ADC) and T2 images by MRI techniques in comparison with histology at the terminal of and after 24-h reperfusion following 2-h occlusion of middle cerebral artery (MCA). The ADC values of tissue water and T2-weighted images were quantified by high field magnetic resonance. No significant difference was observed by ADC image among vehicle and cilostazol treatment groups when measured during MCA occlusion. Oral treatment with cilostazol 30 mg/kg two times at 5 min and 4 h significantly suppressed the hemispheric lesion area and volumes when detected by ADC, T2 images and histology, but 3 and 10 mg/kg cilostazol were without effect. Cilostazol (30 mg/kg) significantly reduced the increased cerebral water content at the ischemic hemisphere compared with vehicle group. In line with these results, the neurological deteriorations were much improved in the cilostazol-treated group. Taken together, it is concluded that post-treatment with cilostazol exerts a potent protective effect against cerebral infarct size by reducing the cytotoxic edema.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642452     DOI: 10.1016/j.brainres.2003.09.021

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

1.  Hypoxic-ischemic brain injury in the neonatal rat model: relationship between lesion size at early MR imaging and irreversible infarction.

Authors:  Y Wang; P-T Cheung; G X Shen; E X Wu; G Cao; I Bart; W H S Wong; P-L Khong
Journal:  AJNR Am J Neuroradiol       Date:  2006-01       Impact factor: 3.825

2.  Cilostazol strengthens barrier integrity in brain endothelial cells.

Authors:  Shoji Horai; Shinsuke Nakagawa; Kunihiko Tanaka; Yoichi Morofuji; Pierre-Oliver Couraud; Maria A Deli; Masaki Ozawa; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.046

Review 3.  Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.

Authors:  Jeong Hyun Lee; So Youn Park; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Ki Whan Hong
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

4.  Neuroprotective Effects of Simvastatin and Cilostazol in L-Methionine-Induced Vascular Dementia in Rats.

Authors:  Ahmed M El-Dessouki; Mai A Galal; Azza S Awad; Hala F Zaki
Journal:  Mol Neurobiol       Date:  2016-08-20       Impact factor: 5.590

5.  Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.

Authors:  Hideki Ito; Ayako Hashimoto; Yutaka Matsumoto; Hiroshi Yao; Goro Miyakoda
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-07       Impact factor: 6.200

6.  Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke.

Authors:  Chongke Zhong; Jingyuan Yang; Tan Xu; Tian Xu; Yanbo Peng; Aili Wang; Jinchao Wang; Hao Peng; Qunwei Li; Zhong Ju; Deqin Geng; Yonghong Zhang; Jiang He
Journal:  Neurology       Date:  2017-07-26       Impact factor: 9.910

7.  Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.

Authors:  Mitsunori Ishiguro; Keisuke Mishiro; Yasuyuki Fujiwara; Huayue Chen; Hiroshi Izuta; Kazuhiro Tsuruma; Masamitsu Shimazawa; Shinichi Yoshimura; Masahiko Satoh; Toru Iwama; Hideaki Hara
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

Review 8.  Animal models of intellectual disability: towards a translational approach.

Authors:  Carla A Scorza; Esper A Cavalheiro
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Supra-additive neuroprotection by renexin, a mixed compound of ginkgo biloba extract and cilostazol, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion.

Authors:  Pil Ae Kwak; Sung Chul Lim; Si-Ryung Han; Young-Min Shon; Yeong-In Kim
Journal:  J Clin Neurol       Date:  2012-12-21       Impact factor: 3.077

10.  Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.

Authors:  Shaheen E Lakhan; Annette Kirchgessner; Deborah Tepper; Aidan Leonard
Journal:  Front Neurol       Date:  2013-04-03       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.